MTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Meritage Homes Corp is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a constructive technical setup and some supportive hedge fund buying, but the lack of recent positive news, multiple analyst target cuts, and mixed options sentiment make this a hold rather than an immediate buy. Since the investor is impatient and wants a direct answer, my view is: do not buy at this moment; wait for a better entry or clearer fundamental catalyst.
Technically, MTH is in a short-term bullish structure: SMA_5 is above SMA_20 and SMA_200, MACD histogram is positive at 0.48, and RSI_6 at 60.85 is neutral-to-bullish without being overbought. Price at 82.2 is sitting above the pivot at 79.78 and below first resistance at 84.48, so momentum is decent but not yet breakout-confirmed. The pattern-based outlook is mixed, with a possible small near-term dip implied by the model, followed by modest upside over the week and month.
Hedge funds have been buying, with buying activity up 123.32% over the last quarter. The technical trend remains bullish across moving averages. UBS still has a Buy rating despite lowering its target. Evercore noted the homebuilders may have already priced in much of the bad news and downside may be manageable. The stock also has a constructive short-term price structure above pivot support.
No news in the recent week means no fresh catalyst to drive immediate upside. Analyst targets have been cut across several firms, including JPMorgan, BofA, Truist, Keefe Bruyette, and Evercore, signaling reduced confidence in near-term earnings and margins. JPMorgan and BofA both hold Neutral-type views, and homebuilder commentary points to softer demand, consumer confidence pressure, and margin concerns. Insider activity is neutral, and there is no congress trading data or influential person buying support.
Latest quarter financials were not available because the financial snapshot returned an error, so there is no reliable quarter-by-quarter growth read to confirm fundamental acceleration. Based on the analyst commentary, however, estimates were reduced after earnings and there are concerns about orders and gross margins, suggesting fundamentals are not currently improving fast enough to justify an aggressive long-term entry.
Analyst sentiment has turned more cautious recently. Several firms lowered price targets: JPMorgan to $58 from $62 and kept Neutral, Keefe Bruyette to $75 from $76 and kept Market Perform, UBS to $86 from $95 but retained Buy, BofA to $72 from $74 and kept Neutral, Truist to $80 from $90 and kept Buy, and Evercore to $69 from $77 with an In Line view. Overall, Wall Street is split but leaning cautious: a few Buy ratings remain, yet the dominant trend is target cuts and tempered expectations, which argues against an immediate aggressive purchase.
